Ideggyogyaszati Szemle-Clinical Neuroscience最新文献

筛选
英文 中文
[Importance of personality disorders in epilepsy]. [人格障碍在癫痫中的重要性]。
IF 0.9 4区 医学
Ideggyogyaszati Szemle-Clinical Neuroscience Pub Date : 2023-09-30 DOI: 10.18071/isz.76.0297
Rita-Judit Kiss, Károly Orbán-Kis, Tibor Szilágyi
{"title":"[Importance of personality disorders in epilepsy].","authors":"Rita-Judit Kiss, Károly Orbán-Kis, Tibor Szilágyi","doi":"10.18071/isz.76.0297","DOIUrl":"10.18071/isz.76.0297","url":null,"abstract":"<p><p>Epilepsy is one of the most common neurological disorders. Therapeutic success shows high variability between patients, at least 20-30% of the cases are drug-resistant. It can highly affect the social status, interpersonal relationships, mental health and the overall quality of life of those affected. Although several studies can be found on the psychiatric diseases associated with epilepsy, only a few researches focus on the occurrence of personality disorders accompanying the latter. The aim of this review is to help clinicians to recognize the signs of personality disorders and to investigate their connection and interaction with epilepsy in the light of current experiences. The researches reviewed in this study confirm that personality disorders and pathological personality traits are common in certain types of epilepsy and they affect many areas of patients' lives. These studies draw attention to the importance of a multidisciplinary approach to this neurological disorder and to provide suggestions about the available help options. Considering the high frequency of epilepsy-related pathological personality traits that can have a great impact on the therapeutic cooperation and on the patients' quality of life, it important that the neurologist recognizes early the signs of the patient's psychological impairment. Thus they can get involved in organizing the support of both the patient and their environment by including psychiatrists, psychologists, social and self-help associations. As interdisciplinary studies show, epilepsy is a complex disease and besides trying to treat the seizures, it is also important to manage the patient's psychological and social situation. Cooperation, treatment response and quality of life altogether can be significantly improved if our focus is on guiding the patient through the possibilities of assistance by seeing the complexity and the difficulties of their situation.</p>","PeriodicalId":50394,"journal":{"name":"Ideggyogyaszati Szemle-Clinical Neuroscience","volume":"76 9-10","pages":"297-307"},"PeriodicalIF":0.9,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41156023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Factors influencing the level of stigma in Parkinson's disease in western Turkey. 影响土耳其西部帕金森病污名化程度的因素。
IF 0.9 4区 医学
Ideggyogyaszati Szemle-Clinical Neuroscience Pub Date : 2023-09-30 DOI: 10.18071/isz.76.0349
Esra Demiryurek, Bekir Enes Demiryurek
{"title":"Factors influencing the level of stigma in Parkinson's disease in western Turkey.","authors":"Esra Demiryurek, Bekir Enes Demiryurek","doi":"10.18071/isz.76.0349","DOIUrl":"10.18071/isz.76.0349","url":null,"abstract":"<p><strong>Background and purpose: </strong>Stigma is a widespread phenomenon in Parkinson's disease (PD) and has been shown to affect the quality of life of individuals. This study aims to assess the level of stigma and identify the factors contributing to stigma in patients with PD in Turkey.</p><p><strong>Methods: </strong>A total of 142 patients diagnosed with PD between June 2022 and March 2023 were included in the study. Sociodemographic data including age, gender, marital status, education level, and duration of PD were collected using a sociodemographic information form. Motor symptom severity was assessed using the Unified Parkinson's Disease Rating Scale (UPDRS part III). The disease stage was determined using the Hoehn and Yahr scale. Participants were classified as PIGD (postural instability/gait difficulty) or TD (tremor dominant) based on the UPDRS score. Patients with a UPDRS ratio greater than or equal to 1.5 were classified as TD, while subjects with a ratio less than or equal to 1.0 were classified as PIGD. Ratios between 1.0 and 1.5 were classified as mixed type. Depression was assessed using the Hamilton Depression Rating Scale (HAM-D), while stigma was measured using the Chronic Illness Anticipated Stigma Scale (CIASS) and the stigma sub-scale of the 39-item Parkinson's Disease Questionnaire (PDQ-39 stigma sub-scale).</p><p><strong>Results: </strong>The mean score on the stigma sub-scale of the PDQ-39 was 7.60±4.39, while the mean total stigma score on the CIASS was 1.37±0.39. Our results indicated that stigma was more prevalent among patients with PD with the TD motor subtype, younger age, shorter disease duration, higher level of disability, and presence of depression symptoms.</p><p><strong>Conclusion: </strong>Our study highlights the association between stigma and disease progression, duration, and depressive symptoms in patients with PD in western Turkey.</p>","PeriodicalId":50394,"journal":{"name":"Ideggyogyaszati Szemle-Clinical Neuroscience","volume":"76 9-10","pages":"349-355"},"PeriodicalIF":0.9,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41150403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Assessment of compliance and patient pathway among multiple sclerosis patients on disease modifying treatment]. [评估多发性硬化症患者对疾病改良治疗的依从性和患者途径]。
IF 0.9 4区 医学
Ideggyogyaszati Szemle-Clinical Neuroscience Pub Date : 2023-09-30 DOI: 10.18071/isz.76.0309
Klotild Mátyás, Tamás Bobál, Zsolt Abonyi
{"title":"[Assessment of compliance and patient pathway among multiple sclerosis patients on disease modifying treatment].","authors":"Klotild Mátyás, Tamás Bobál, Zsolt Abonyi","doi":"10.18071/isz.76.0309","DOIUrl":"10.18071/isz.76.0309","url":null,"abstract":"<p><strong>Background and purpose: </strong>Epidemiological data and the number of patients treated suggest that the proportion of Hungarian patients with Multiple Sclerosis (MS) receiving disease-modifying therapy (DMT) is lower than in some neighboring countries. We investigated possible reasons for this.</p><p><strong>Methods: </strong>First we analysed patient compliance based on an anonymised database of the National Health Insurance Fund (NHIF). A total of 5441 patients were included in the analysis from NHIF prescription data from 1 July 2014 to 28 February 2021. In the second part of the study, a quantitative and qualitative assessment of patient journeys of MS patients was conducted.</p><p><strong>Results: </strong>The compliance of Hungarian MS patients is good compared to international MS treatment data and outstanding compared to other neurological and other diseases, e.g. cardiovascular. This cannot be said about the results of the patient pathway analysis based on patient interviews. Patients indicated that they often have difficulty accessing public health care. Tracing their pathways revealed that they needed to see 3-5 doctors (general practitioner, various specialists) before a diagnosis was made. However, they gave positive feedback about MS Centres. They trusted their doctors, found them empathetic, but they would have liked more time to discuss lifestyle issues.</p><p><strong>Conclusion: </strong>Compared to some neighbouring countries, Hungary has a lower proportion of patients with treated MS, which, given the good compliance of patients, highlights the problem of patient path in Hungary. Further training of fellow physicians is also a task for neurologists specialising in MS. Just as the most common symptoms of stroke have been successfully introduced into the public consciousness, the same can be the aim for MS.</p>","PeriodicalId":50394,"journal":{"name":"Ideggyogyaszati Szemle-Clinical Neuroscience","volume":"76 9-10","pages":"309-317"},"PeriodicalIF":0.9,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41105803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neurobehavioral impairments in ciprofloxacin- treated osteoarthritic adult rats. 环丙沙星治疗的成年骨关节炎大鼠的神经行为损伤。
IF 0.9 4区 医学
Ideggyogyaszati Szemle-Clinical Neuroscience Pub Date : 2023-09-30 DOI: 10.18071/isz.76.0327
Gabriella Kékesi, Eszter Ducza, Hristifor Gálity, Alexandra Büki, Kálmán Tóth, Gábor Tuboly, Gyöngyi Horváth
{"title":"Neurobehavioral impairments in ciprofloxacin- treated osteoarthritic adult rats.","authors":"Gabriella Kékesi, Eszter Ducza, Hristifor Gálity, Alexandra Büki, Kálmán Tóth, Gábor Tuboly, Gyöngyi Horváth","doi":"10.18071/isz.76.0327","DOIUrl":"10.18071/isz.76.0327","url":null,"abstract":"<p><strong>Background and purpose: </strong>Ciprofloxacin (CIP) is a broad-spectrum antibiotic widely used in clinical practice to treat musculoskeletal infections. Fluoroquinolone-induced neurotoxic adverse events have been reported in a few case reports, all the preclinical studies on its neuropsychiatric side effects involved only healthy animals. This study firstly investigated the behavioral effects of CIP in an osteoarthritis rat model with joint destruction and pain, which can simulate inflammation-associated musculoskeletal pain. Furthermore, effects of CIP on regional brain-derived neurotrophic factor (BDNF) expression were examined given its major contributions to the neuromodulation and plasticity underlying behavior and cognition.</p><p><strong>Methods: </strong>Fourteen days after induction of chronic osteoarthritis, animals were administered vehicle, 33 mg/kg or 100 mg/kg CIP for five days intraperitoneally. Motor activity, behavioral motivation, and psychomotor learning were examined in a reward-based behavioral test (Ambitus) on Day 4 and sensorimotor gating by the prepulse inhibition test on Day 5. Thereafter, the prolonged BDNF mRNA and protein expression levels were measured in the hippocampus and the prefrontal cortex.</p><p><strong>Results: </strong>CIP dose-dependently reduced both locomotion and reward-motivated exploratory activity, accompanied with impaired learning ability. In contrast, there were no significant differences in startle reflex and sensory gating among treatment groups; however, CIP treatment reduced motor activity of the animals in this test, too. These alterations were associated with reduced BDNF mRNA and protein expression levels in the hippocampus but not the prefrontal cortex.</p><p><strong>Conclusion: </strong>This study revealed the detrimental effects of CIP treatment on locomotor activity and motivation/learning ability during osteoarthritic condition, which might be due to, at least partially, deficient hippocampal BDNF expression and ensuing impairments in neural and synaptic plasticity.</p>","PeriodicalId":50394,"journal":{"name":"Ideggyogyaszati Szemle-Clinical Neuroscience","volume":"76 9-10","pages":"327-337"},"PeriodicalIF":0.9,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41150701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic value of indoleamine 2, 3-dioxygenase-1 expression in glial tumors. 吲哚胺2,3-二加氧酶-1在神经胶质瘤中的表达对预后的价值。
IF 0.9 4区 医学
Ideggyogyaszati Szemle-Clinical Neuroscience Pub Date : 2023-09-30 DOI: 10.18071/isz.76.0339
Munir Kaya, Asude Aksoy, Gokhan Artas, Metin Kaplan
{"title":"Prognostic value of indoleamine 2, 3-dioxygenase-1 expression in glial tumors.","authors":"Munir Kaya, Asude Aksoy, Gokhan Artas, Metin Kaplan","doi":"10.18071/isz.76.0339","DOIUrl":"10.18071/isz.76.0339","url":null,"abstract":"<p><strong>Background and purpose: </strong>Gliomas are the most common primary malignant central nervous system tumors in adults, exhibiting a poor prognosis. Indoleamine 2, 3-dioxygenase-1 (IDO-1) has important functions in cancer immunotherapy due to its role in escaping cancer cells from the immune system. In this study we purposed to evaluate the correlation between IDO-1 expression and clinicopathological parameters in gliomas, and whether IDO-1 can be a prognostic marker.</p><p><strong>Methods: </strong>n=75 patients in total, n=25 patients with low grade glial tumors (LGG, grade 1-2), n=25 patients with high grade glial tumors (HGG, grade 3-4), and n=25 persons with normal brain tissue as control group were included in this study. IDO-1 expression was categorized by using immunohistochemical staining in biopsy specimens as high (H) and low (L) groups among the patients with gliomas. We used a 95% percent confidence interval and p <0.05 to analyze the association between the degree of IDO-1 expression, clinicopathological characteristics, and survival rates in glioma patients.</p><p><strong>Results: </strong>In HGG, IDO-1 levels were higher than in control brain tissue and LGG (p< 0.001). The mean overall survival (OS) was longer in the L-IDO-1 group (64.53 ± 3.34) in months (95% CI: 57.969-71.098) compared to the H-IDO-1 group (43.74 ± 4.36) in months, (95% CI: 35.218-52.330) (p< 0.05).</p><p><strong>Conclusion: </strong>IDO-1 expression is an independent prognostic biomarker to predict and progression in HGG. IDO-1 can be evaluated as an alternative instrument for precision medicine in the treatment of gliomas.</p>","PeriodicalId":50394,"journal":{"name":"Ideggyogyaszati Szemle-Clinical Neuroscience","volume":"76 9-10","pages":"339-347"},"PeriodicalIF":0.9,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41173751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[How our view of epileptogenesis and mechanism of epilepsy changes? The system epilepsies' concept]. 我们对癫痫发生和癫痫机制的看法如何改变?系统癫痫的概念]。
IF 0.8 4区 医学
Ideggyogyaszati Szemle-Clinical Neuroscience Pub Date : 2022-03-31 DOI: 10.18071/isz.75.0079
P. Halász, A. Szűcs
{"title":"[How our view of epileptogenesis and mechanism of epilepsy changes? The system epilepsies' concept].","authors":"P. Halász, A. Szűcs","doi":"10.18071/isz.75.0079","DOIUrl":"https://doi.org/10.18071/isz.75.0079","url":null,"abstract":"Background and purpose\u0000To examine the ways of epileptogenesis closely linked to the system epilepsies' concept.\u0000\u0000\u0000Methods\u0000We follow the ways of epileptic transformation in the declarative memory-system, in the sleep/arousal twin-systems, in the perisylvian neuronal network and in postinjury epilepsy, which we consider a general model of the epileptic transformation.\u0000\u0000\u0000Results\u0000In the presented systems, epileptogenesis shares a similar mechanism in the form of augmentation and derailment of plasticity and sleep-related synaptic homeo-stasis. This highlights the central role of NREM sleep in those epilepsies.\u0000\u0000\u0000Conclusion\u0000We try to characterize the concept of system epilepsies and suggest a shared mechanism of epileptogenesis.","PeriodicalId":50394,"journal":{"name":"Ideggyogyaszati Szemle-Clinical Neuroscience","volume":"75 3-04 1","pages":"79-97"},"PeriodicalIF":0.8,"publicationDate":"2022-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67669625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[New, innovative prognosis calculator for patients with metastatic spinal tumors]. [新的,创新的预后计算器为转移性脊柱肿瘤患者]。
IF 0.8 4区 医学
Ideggyogyaszati Szemle-Clinical Neuroscience Pub Date : 2022-03-31 DOI: 10.18071/isz.75.0117
T. Mezei, J. Báskay, P. Pollner, A. Horváth, Z. Nagy, G. Czigléczki, P. Banczerowski
{"title":"[New, innovative prognosis calculator for patients with metastatic spinal tumors].","authors":"T. Mezei, J. Báskay, P. Pollner, A. Horváth, Z. Nagy, G. Czigléczki, P. Banczerowski","doi":"10.18071/isz.75.0117","DOIUrl":"https://doi.org/10.18071/isz.75.0117","url":null,"abstract":"Background and purpose\u0000The aim of our research was to create a scoring system that predicts prognosis and recommends therapeutic options for patients with metastatic spine tumor. Increasing oncological treatment opportunities and prolonged survival have led to a growing need to address clinical symptoms caused by meta-stases of the primary tumor. Spinal metastases can cause a significant reduction in quality of life due to the caused neurological deficits. A scoring system that predicts prognosis with sufficient accuracy could help us to achieve personalised treatment options.\u0000\u0000\u0000Methods\u0000Methods - We performed a retrospective clinical research of data from patients over 18 years of age who underwent surgery due to symptomatic spinal metastasis at the National Institute of Mental Disorders, Neurology and Neurosurgery between 2008 and 2018. Data from 454 patients were analysed. Survival analysis (Kaplan-Meier, log-rank, Cox model) was performed, network science-based correlation analysis was used to select the proper prognostic factors of our scoring system, such that its C value (predictive ability index) was maximized.\u0000\u0000\u0000Results\u0000Multivariate Cox analysis resulted in the identification of 5 independent prognostic factors (primary tumour type, age, ambulatory status, internal organ metastases, serum protein level). Our system predicted with an average accuracy of 70.6% over the 10-year study period.\u0000\u0000\u0000Conclusion\u0000Our large case series of surgical dataset of patients with symptomatic spinal metastasis was used to create a risk calculator system that can help in the choice of therapy. Our risk calculator is also available online at https://emk.semmelweis.hu/gerincmet.","PeriodicalId":50394,"journal":{"name":"Ideggyogyaszati Szemle-Clinical Neuroscience","volume":"75 3-04 1","pages":"117-127"},"PeriodicalIF":0.8,"publicationDate":"2022-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67669686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Myasthenia gravis, Guillain-Barré-szindróma, vagy mindkettő?
IF 0.8 4区 医学
Ideggyogyaszati Szemle-Clinical Neuroscience Pub Date : 2020-01-01 DOI: 10.18071/ISZ.HTTPS://DOI.ORG/10.18071/ISZ.73.0060
Çağdaş Erdoğan, Selma Tekin, Zeynep Ünlütürk, Derya Korkut Gedik
{"title":"Myasthenia gravis, Guillain-Barré-szindróma, vagy mindkettő?","authors":"Çağdaş Erdoğan, Selma Tekin, Zeynep Ünlütürk, Derya Korkut Gedik","doi":"10.18071/ISZ.HTTPS://DOI.ORG/10.18071/ISZ.73.0060","DOIUrl":"https://doi.org/10.18071/ISZ.HTTPS://DOI.ORG/10.18071/ISZ.73.0060","url":null,"abstract":"","PeriodicalId":50394,"journal":{"name":"Ideggyogyaszati Szemle-Clinical Neuroscience","volume":"126 1","pages":"60-64"},"PeriodicalIF":0.8,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85321991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Valproinsav-használat mellékhatásaként kialakuló PLeuropericardialis folyadékgyülem
IF 0.8 4区 医学
Ideggyogyaszati Szemle-Clinical Neuroscience Pub Date : 2020-01-01 DOI: 10.18071/ISZ.HTTPS://DOI.ORG/10.18071/ISZ.73.0070
Ulku Fıgen Demir
{"title":"Valproinsav-használat mellékhatásaként kialakuló PLeuropericardialis folyadékgyülem","authors":"Ulku Fıgen Demir","doi":"10.18071/ISZ.HTTPS://DOI.ORG/10.18071/ISZ.73.0070","DOIUrl":"https://doi.org/10.18071/ISZ.HTTPS://DOI.ORG/10.18071/ISZ.73.0070","url":null,"abstract":"","PeriodicalId":50394,"journal":{"name":"Ideggyogyaszati Szemle-Clinical Neuroscience","volume":"29 1","pages":"70-72"},"PeriodicalIF":0.8,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89738666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Marchiafava-Bignami-betegség: három eset ismertetése
IF 0.8 4区 医学
Ideggyogyaszati Szemle-Clinical Neuroscience Pub Date : 2020-01-01 DOI: 10.18071/ISZ.HTTPS://DOI.ORG/10.18071/ISZ.73.0065
Günay Gül, Mesude Özerden, Zeynep Ozdemir, Cahit Keskinkiliç, Hakan Selcuk, Batuhan Kara, Aysun Soysal
{"title":"Marchiafava-Bignami-betegség: három eset ismertetése","authors":"Günay Gül, Mesude Özerden, Zeynep Ozdemir, Cahit Keskinkiliç, Hakan Selcuk, Batuhan Kara, Aysun Soysal","doi":"10.18071/ISZ.HTTPS://DOI.ORG/10.18071/ISZ.73.0065","DOIUrl":"https://doi.org/10.18071/ISZ.HTTPS://DOI.ORG/10.18071/ISZ.73.0065","url":null,"abstract":"","PeriodicalId":50394,"journal":{"name":"Ideggyogyaszati Szemle-Clinical Neuroscience","volume":"48 1","pages":"65-69"},"PeriodicalIF":0.8,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74155542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信